01
Bill activity
Shows that a policy proposal entered the legislative process. It does not by itself establish funding, change federal scheduling, or authorize a clinical study.
Texas pathway · dates, decisions, constraints
Program Timeline
A chronological view of the public policy, funding, institutional, and regulatory milestones shaping Texas ibogaine research—and the unresolved steps between an announced program and FDA-authorized trials.
Timeline entries distinguish reported activity from completed federal authorization. They do not indicate legalization, clinical availability, or patient eligibility.
RESEARCH PATHWAY
NOT ROUTINE ACCESS
NOT ROUTINE ACCESS
How to read this page
A record of the pathway, not a promise of access.
Texas discussion of ibogaine has moved through legislative proposals, public appropriations, university and consortium announcements, and anticipated federal research work. Each is consequential, but none substitutes for the FDA and DEA steps required to conduct lawful research with a controlled substance.
For broader context on why authorization, oversight, and trial design matter, the Texas research pathway overview separates public program activity from the federal processes that govern a study. The main Texas research context also frames the distinction between research authorization and routine treatment access.
Chronology
From state proposal to trial-planning work.
Ibogaine is listed by the DEA as a Schedule I controlled substance. That classification makes research possible only within specific federal controls; it does not create a general treatment exception.
Federal scheduling context is described in the DEA’s controlled-substance scheduling guidance, which is why state-level momentum still depends on federal permissions.
-
Earlier local activity · before 2025
Texas interest develops alongside national research discussion.
Public attention in Texas included veteran-focused advocacy, policy discussion, and interest in whether ibogaine could be studied in a rigorously supervised setting. This activity signaled demand for a research pathway, but it did not establish a Texas-authorized treatment market or an FDA-approved indication.
Sources: Public legislative and institutional discussion; general federal context from the ibogaine reference overview. Why it matters: It establishes the policy background from which later bills and program proposals emerged.
-
2025 legislative session
SB 2308 places ibogaine research in the Texas policy conversation.
SB 2308 was introduced as part of the state-level discussion around supporting ibogaine research. Bill introduction is an early procedural milestone: it records a proposed public policy mechanism, but it is not itself an appropriation, a trial authorization, or a change to federal law.
Sources: Texas legislative materials for SB 2308. Why it matters: A bill can shape the route for funding or state participation, while FDA and DEA requirements remain separately applicable.
-
2025 budget and award discussion
A reported $50 million award becomes a central program marker.
Public reporting described a $50 million Texas award connected to the planned research effort. The amount is best understood as a funding milestone rather than evidence of a completed trial, demonstrated clinical outcome, or generally available service. Publicly discussed matching-fund and award-condition details remain important implementation questions.
Sources: Public state funding and institutional announcements. Why it matters: Funding can support study infrastructure and planning, but the terms, matching requirements, and allowable uses determine how quickly an initiative can advance.
-
2025 public announcements
UTHealth Houston, UTMB, and the IMPACT consortium identify a research direction.
Public announcements by UTHealth Houston and the University of Texas Medical Branch, associated with the IMPACT consortium, described an intention to build a Texas-based research program. Institutional participation is meaningful because federally regulated clinical research requires accountable study sites, protocols, monitoring, and review structures.
Sources: UTHealth Houston, UTMB, and IMPACT consortium public communications. Why it matters: Naming institutional participants is a planning milestone, not confirmation that an IND has been cleared or that enrollment has begun.
-
2025–2026 federal preparation
FDA and DEA interaction remains a required bridge.
Before an interventional U.S. trial can proceed, sponsors typically prepare a protocol and seek the applicable FDA investigational pathway, alongside controlled-substance registrations, security, sourcing, and recordkeeping obligations. The FDA explains that an Investigational New Drug application is the mechanism used to seek authorization to administer an investigational drug to humans in a clinical study.
Sources: FDA IND guidance and DEA scheduling framework. Why it matters: Publicly announced program planning should not be read as proof that an IND is active, accepted, or cleared unless the responsible institution confirms that status.
-
2026 and near-term steps
Trial planning remains contingent on documented approvals and readiness.
Near-term work may include protocol refinement, institutional review board review, federal submissions, investigator and site preparation, drug-control procedures, and funding compliance. These are distinct checkpoints. Until they are publicly confirmed, recruitment dates, participant access, and treatment claims remain unresolved.
Sources: Public program statements and standard U.S. research requirements. Why it matters: A credible timeline preserves uncertainty instead of converting plans into presumed facts.
Milestone decoder
What each public signal can—and cannot—show.
02
Funding announcement
Shows intended support, subject to award terms, appropriation mechanics, and any stated matching-fund requirements. It is not a safety or efficacy conclusion.
03
Institutional announcement
Shows a proposed research partnership or direction. It does not confirm that an FDA submission, DEA registration, participant enrollment, or trial start has occurred.
04
Federal trial authorization
Requires its own documented pathway. An IND, controlled-substance compliance, study oversight, and institutional approvals are not interchangeable milestones.
State support can accelerate research preparation without changing the legal status of a drug or making care routinely available.
Why the distinction matters
The record should stay ahead of the rhetoric.
Ibogaine’s legal classification and the requirements for clinical investigation mean that public funding and institutional interest are only parts of the pathway. Neither should be treated as medical guidance, a claim of clinical benefit, or a notice that a research participant can obtain ibogaine outside an authorized study.
The stakeholder implications guide examines how the same uncertainty can affect veterans, families, clinicians, researchers, and policymakers differently. For people following developments outside Texas, the Florida ibogaine treatment context likewise requires care in separating treatment marketing from the specific legal and research status in a given place.
Open questions
What has not been settled by an announcement.
These are the recurring questions that should be checked against current public documents as the Texas program develops.
Does the Texas program mean ibogaine is legal for routine treatment?
No. Research activity, state support, or trial planning does not itself authorize routine clinical treatment. Federal controlled-substance rules and FDA authorization pathways remain relevant.
What remains unresolved?
Publicly discussed next steps can include DEA scheduling constraints, FDA IND review, protocol development, institutional approvals, matching-fund requirements, and recruitment planning. Their completion should not be presumed until publicly confirmed.
What does a reported $50 million award represent?
A reported award is a funding milestone, not a finding of safety, effectiveness, or routine availability. Its practical use depends on the governing award terms, institutional steps, and applicable federal requirements.
Keep the sequence clear
Follow the documented steps, not the implied shortcuts.
As new public records appear, the meaningful question is which discrete milestone has actually occurred—and which federal, institutional, and funding conditions still remain.